Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) Overview 2019: A Third-Generation, Type II Glycoengineered, Humanized Anti-CD20 Monoclonal Antibody (MAb)...
DUBLIN--(BUSINESS WIRE)--Jul 12, 2019--
DUBLIN--(BUSINESS WIRE)--Jul 12, 2019--